Early warning scores (EWS) were introduced in early 2001 to identify patients at risk of deterioration in a busy clinical environment as a track-and-trigger system where an increasing score produced an escalated response. 1 EWS have demonstrated better capability in identifying deteriorating patients leading to improved clinical outcomes. 2 Furthermore, an EWS at admission can be used to determine in-hospital mortality and intensive care unit (ICU) transfer. 2-4 Our academic medical center developed a modified early warning score (MEWS) system in 2015 and it was rolled out hospital-wide the following year. Since serious adverse events in hospitalized patients are often preceded by signs of clinical deterioration, we believed MEWS scores could be used to predict events, such as cardiopulmonary arrest. As the coronavirus pandemic continues, could MEWS provide any usefulness in predicting ICU level care among hospitalized COVID-19 patients? A retrospective study was conducted at the University of Toledo Medical Center (Toledo, OH) on COVID-19 positive patients hospitalized from late March to the end of May 2020. All patients were confirmed for COVID-19 by real-time reverse transcription polymerase chain reaction. Patient demographics, biometrics, and comorbidities were gathered from the electronic medical record. The highest level of hospital disposition was used to create the medical floor and ICU groups. The MEWS scores, which are calculated hourly using the criteria in Fig. 1 , were retrieved from an electronic database. Initial MEWS scores were considered either at admission or prior to ICU transfer. Sequential organ failure assessment (SOFA)
BackgroundRapid diagnostic tests (RDTs), such as Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF), have been shown to improve time to effective therapy and positively impact patient outcomes when used along with antimicrobial stewardship team (AST) intervention in treating bloodstream infections (BSIs). The purpose of this study was to assess the impact of MALDI-TOF (implemented May 25, 2016) and AST intervention on management of BSIs at a smaller, resource-limited institution.MethodsIRB-approved, single-center, pre-post quasi-experiment including all patients treated for BSI at the University of Toledo Medical Center from November 1, 2015-November 30, 2016. Patients transferred with documented BSI, expired prior to organism identification, or had blood culture positive for Mycobacterium, Nocardia, anaerobes, or molds were excluded. Primary endpoint: time to effective therapy. Secondary endpoints: time to optimal therapy, hospital length of stay (LOS), recurrent bacteremia, and 30-day readmission and all-cause mortality.Results593 blood cultures screened, 261 included; 131 pre- and 130 post-MALDI-TOF implementation. Baseline characteristics similar between groups. Median (IQR) time to effective therapy was 6.1 h (2.3–20.0) pre-MALDI-TOF and 6.4 hours (2.2–23.7) post-MALDI-TOF, P = 0.609. Median (IQR) time to optimal therapy was 67.3 (48.6–93.2) pre-MALDI-TOF and 67.2 (44.3–94.0) post-MALDI-TOF, P = 0.520. Secondary endpoints shown in Table 1. In a subset of cultures defined as contaminants, reduction was seen in time to discontinuation of therapy, however not statistically significant (93.8 hours (61.8–131.4) vs. 71.1 hours (57.5–106.3); P = 0.180).ConclusionImplementation of MALDI-TOF and AST intervention did not significantly improve an already prompt time to effective therapy in patients with BSIs at our institution. Time to optimal therapy was also similar, highlighting the need for more rapid susceptibility tests in order to support earlier de-escalation of therapy.Table 1.Clinically Evaluable EndpointsPre-MALDI-TOF
(n = 108)Post-MALDI-TOF
(n = 104)P-valueHospital LOS (days)9.1 (6.2–15.6)10.0 (6.3–15.7)0.823Recurrent bacteremia6 (5.6)4 (3.8)0.74830-day readmission24 (22.2)18 (17.3)0.36930-day, all-cause mortality16 (14.8)19 (18.3)0.498Values reported as median (IQR) or n(%).Disclosures
All authors: No reported disclosures.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.